University of California

Relia Diagnostic Systems, LLC

Other

Humabs Biomed Sa

Avirus, Inc.

University of Washington

Washington Research Foundation

Relia Biotechnologies Ltd.

William J Rutter

Howard M Goodman

Daniel V Santi

Jang Hyun Han

Benjamin D Hall

Gustav Ammerer

Raymond Pictet

Axel Ullrich

Pablo D Valenzuela

Robert A Hallewell

John Shine

Jeffrey C Edman

Taewoo Kwon

John Chirgwin

Pablo D T Valenzuela

Jeffrey D Johnson

Davide Corti

Thomas Edlund

Robert H Edwards

Mi-Young Seo

Siliang Zhou

Ning Liu

Anne M Boulet

Michael D Wlaker

Graeme Bell

Jang H Han

The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.

Methods and compositions for treating and preventing viral infection

The invention relates to methods of generating a robust passive and an active immune response in a subject comprising administering a neutralizing antibody and a pathogen to the subject. The invention also relates to kits and pharmaceutical compositions useful in generating a robust passive and an active immune response in a subject.

Methods of generating robust passive and active immune responses

Described herein are systems and methods for the quantitative analysis of a sample comprising glycated hemoglobin. Also described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample, for example, in a blood sample. The methods and systems described herein may be used in a point-of-care device as well as in other in vitro diagnostic devices.

Systems and methods for determining the percentage of glycated hemoglobin

Described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample.

The present invention relates to a lateral flow assay and system, including a test strip, for detection and quantification of analytes in samples, such as samples containing cells and fluid. In general, according to the present invention, a test strip for a lateral flow assay for detection of at least one analyte in a sample comprises: (1) a chromatographic strip, a sample filter, a fluid-impermeable barrier, and means for providing a mobilizable detectable agent that is capable of binding to the at least one analyte or to the capture agent after capturing the analyte to the chromatographic strip such that the mobilizable detectable agent migrates through the chromatographic strip and contacts sample that has passed through the sample filter and also has migrated through the chromatographic strip. The test strip allows detection with or without quantitation of an analyte in a sample containing whole cells.

Lateral flow system and assay

A telephone line shunt for disabling incoming and outgoing calls to or from a telephone line. The device attaches to a single outlet or telephone such that the line is unavailable to devices attached to it from any other location. A shunt short circuits the ring and pitch lines of a conventional telephone line to inhibit a dial tone for outgoing calls while simultaneously creating the appearance of a line busy status for incoming calls. The shunt is inserted into any standard telephone wall jack to inhibit line availability, and removed to restore line availability. The shunt can be implemented by a simple wire shunt embedded in a modified plug for an RJ-11 jack. Alternatively, the shunt can be controlled by activation switches on a wall receptacle, on a telephone hand set, and on a telephone/clock radio. An optional remote control allows switching of the shunt. The shunt control mechanism may also used a password system to control access to the shunt.

Telephone line isolation device and method of use

A breast carcinoma tyrosine phosphoprotein, DDR (Discoidin Domain Receptor), that defines a novel class of receptor tyrosine kinases is presented. The DDR cDNA predicts a polypeptide C-terminal tyrosine kinase domain and an N-terminal domain similar to the lectin discoidin I. These domains are connected by an extraordinary hydrophilic proline/glycine-rich domain, which is interrupted by a predicted transmembrane sequence. This extended proline/glycine-rich region suggests an unusual geometry of interaction with ligand or substrates. Discoidin I-type domains may interact with specific cell surface molecules.

Receptor tyrosine kinase with a discoidin-type binding domain

The present invention relates to synthesis of HB Ag in yeast. Yeast expression vectors comprising a yeast promoter, ADH1, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector. Using the described yeast vector, the successful synthesis of HB Ag by yeast has been achieved. The product is antigenic (reactive with anti-HB Ag), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HB Ag synthesized by yeast has identical sedimentation behavior to purified, naturally occurring HB Ag particles purified from Alexander cells as measured by sucrose gradient sedimentation. The present invention demonstrates synthesis and assembly of a higher ordered multi-component structure resulting from expression of a heterologous DNA coding segment in a microorganism.

Synthesis of human virus antigens by yeast

The present invention relates to synthesis of HBsAg in yeast. Yeast expression vectors comprising a yeast promoter, ADH1, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector. Using the described yeast vector, the successful synthesis of HBsAg by yeast has been achieved. The product is antigenic (reactive with anti-HBsAg), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBSAg synthesized by yeast has identical sedimentation behavior to purified, naturally-occurring HBsAq particles purified from Alexander cells as measured by sucrose gradient sedimentation. The present invention demonstrates synthesis and assembly of a higher ordered multi-component structure resulting from expression of a heterologous DNA coding segment in a microorganism.

A method to obtain selected individual peptides or families thereof which have a target property and optionally to determine the amino acid sequence of a selected peptide or peptides to permit synthesis in practical quantities is disclosed. In general outline, the method of the invention comprises synthesizing a mixture of randomly or deliberately generated peptides using standard synthesis techniques, but adjusting the individual concentrations of the components of a mixture of sequentially added amino acids according to the coupling constants for each amino acid/amino acid coupling. The subgroup of peptides having the target property can then be selected, and either each peptide isolated and sequenced, or analysis performed on the mixture to permit its composition to be reproduced. Also included in the invention is an efficient method to determine the relevant coupling constants.

Peptide mixtures

A method for producing pure, active, mature recombinant Nerve Growth Factor-beta is disclosed, as is the protein so produced.

Recombinant nerve growth factor

General method for producing and selecting peptides with specific

More effectively controlled expression of DNA sequences in coding desired heterologous proteins is achieved in differentiated eucaryotic cells by methods of this invention. Disclosed herein are control modules derived from selectively expressed genes of eucaryotic cells, such as, for example, insulin and chymotrypsin genes. These control elements contain cis-acting sequences which are responsive to indigenous trans-acting substances in the differentiated cell, which substances control the expression of the gene. Such cis-acting elements occur within the promoter region of such selectively expressed genes, and also in the five prime flanking region of the coding sequence in a position upstream of the promoter. These upstream enhancer sequences may be located using the methods disclosed herein, and ligated into differentiative expression modules for production of desired heterologous proteins.

Differentiative expression modules

Method of obtaining a peptide with desired target property

The present invention is directed to an expression vector containing DNA which encodes recombinant full-length hepatitis B surface antigen protein wherein said vector is free of DNA encoding hepatitis B core antigen protein in a microorganism.

Growing community of inventors

San Francisco, CA, United States of America

William J Rutter